Navigation Links
DuPont and Plantic Technologies Announce Starch-Based Bio Materials Collaboration
Date:9/26/2007

made with Plantic technology in all markets except Australia and New Zealand, using the DuPont(TM) Biomax(R) brand.

"This agreement with DuPont helps Plantic expand the reach of its renewably sourced polymer technology around the world, and significantly enhances the opportunities for product development for this technology by tapping into one of the world's leading science companies," Plantic CEO Grant Dow said.

DuPont's unique breadth of biology, chemistry and materials science, ranging from better seeds to value-added end-use products, has enabled the creation of DuPont(TM) Renewably Sourced Materials, where each product contains a minimum of 20 percent renewable content by weight. These high- performance products are sourced to a significant extent from renewable, sustainable agricultural feedstocks, rather than petroleum. Renewably Sourced Materials from DuPont help reduce the environmental footprint, promote rural development and larger markets for farmers around the world, and help reduce dependence on petrochemicals for everyday products. Plantic-based products will be part of a growing suite of products being marketed under the DuPont(TM) Renewably Sourced Materials initiative (http://www.renewable.dupont.com).

Plantic's novel polymer manufacturing technology is based on the use of high-amylose corn starch, a material derived from annual harvesting of specialized (hybrid) corn. The unique chemical and film-forming properties of this type of corn starch allow for development of a range of applications across conventional plastics markets. In addition to being renewably sourced, users can take advantage of excellent end-of-life properties such as biodegradability and compostability.

Plantic Technologies Limited has emerged as a world leading bioplastics innovator. The Australia-based company has won numerous international awards for achievement in science and has built an inte
'/>"/>

SOURCE DuPont
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Barriers will not stop convergence of medical technologies
2. Merge Technologies net loss doubles to $10.1M
3. Making deals with evolving technologies in mind
4. Third Wave Technologies to raise $14.9M through private debt
5. Meier joins Broadlook Technologies as COO
6. Platypus Technologies secures $450K SBIR grant
7. Napier joins board of Third Wave Technologies
8. aOva Technologies raises $3 million
9. Consumer, business technologies face same challenges
10. Promega to get early access to WARF technologies under new agreement
11. Linda Weber to run Fiservs Interactive Technologies unit
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3
Breaking Biology News(10 mins):Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Munich lab demonstrates diesel truck engine with barely measurable emissions 2Munich lab demonstrates diesel truck engine with barely measurable emissions 3HOWARU 28R 29 Protect Clinically Shown to Reduce the Incidence and Severity of Cold and Flu Symptoms in Children 52951 1HOWARU 28R 29 Protect Clinically Shown to Reduce the Incidence and Severity of Cold and Flu Symptoms in Children 52951 2Humanitas Designated as Approved Provider by California Board of Registered Nursing for Continuing Education Course Credit and Units 52948 1Humanitas Designated as Approved Provider by California Board of Registered Nursing for Continuing Education Course Credit and Units 52948 2Humanitas Designated as Approved Provider by California Board of Registered Nursing for Continuing Education Course Credit and Units 52948 3TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 52945 1TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 52945 2TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 52945 3TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 52945 4